HSC Stock Recent News

Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy Data reinforces continued development as a potentially transformative, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that new data from a study in non-human primates (NHPs) has been accepted for a poster presentation at the European Hematology Association (EHA) 2025 Congress being held June 12-15, 2025, in Milan, Italy.

Located in Murga, Basque Country, Spain, the new plant will offer environmental asphalt solutions to the region Steel Phalt ™ offers a true circular economy route for byproducts of the steel industry, offering high-quality asphalt without the use of natural aggregates ROTHERHAM, United Kingdom, March 13, 2025 (GLOBE NEWSWIRE) -- Harsco Environmental, a division of Enviri Corporation (NYSE: NVRI) and renowned global market leader in delivering innovative environmental solutions, today announced the opening of a new, state-of-the-art SteelPhalt plant in Murga, Basque Country, Spain. The plant is slated to host a grand opening event on March 19, 2025.

PHILADELPHIA, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Harsco Environmental, a division of Enviri Corporation (NYSE: NVRI), today announced the signing of a contract with İzmir Demir Çelik Sanayi A.Ş. (İDÇ) in İzmir, Turkey.

First U.S. patients being treated with Lenmeldy™ (atidarsagene autotemcel) in a commercial setting; other launch efforts progressing well following Food and Drug Administration approval last year

Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic function in a variety of tissues and organs, including the CNS Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic function in a variety of tissues and organs, including the CNS

- Investigator-initiated study includes leading researchers in SCD gene therapy clinical development from St. Jude Children's Research Hospital, Inc. and two other clinical sites -   - New trial to expand ongoing clinical research of motixafortide for mobilization of HSCs in patients with SCD - TEL AVIV, Israel , May 30, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced a multi-center Phase 1 clinical trial sponsored  by St. Jude Children's Research Hospital, Inc. to evaluate motixafortide for the mobilization of CD34+ hematopoietic stem cells (HSCs) used in the development of gene therapies for patients with sickle cell disease (SCD).

Harsco Corp. HSC, +6.26% said Monday it has changed its name to Enviri Corp., effective immediately. Enviri Corp. will begin trading under the NYSE ticker “NVRI” on June 19.

Here is how Crawford (CRD.A) and Harsco (HSC) have performed compared to their sector so far this year.

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Harsco (HSC) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

The mean of analysts' price targets for Harsco (HSC) points to a 25.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.